NCT06714773 is a clinical trial in Chondrosarcoma, Grade 2, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who is sponsoring NCT06714773?

NCT06714773 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What condition does NCT06714773 study?

NCT06714773 studies Chondrosarcoma, Grade 2.

Is NCT06714773 still recruiting?

NCT06714773 is currently completed. Last updated 4 December 2024.

Last reviewed 2024-12-04 · How we verify

NCT06714773

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Grade 2 Chondrosarcoma Treated by Intralesional Curettage: Follow-up vs Resection

Completed Last updated 4 December 2024

What this trial tests

trial in Chondrosarcoma, Grade 2 in 62 participants. Completed in 1 August 2024.

Timeline

20 January 2024

Primary endpoint
20 July 2024

1 August 2024

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status	Completed
Study type	OBSERVATIONAL
Enrollment	62
Start date	20 January 2024
Primary completion	20 July 2024
Estimated completion	1 August 2024
Sites	1 location across Italy

Conditions studied

Chondrosarcoma, Grade 2 — all drugs for Chondrosarcoma, Grade 2 →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Chondrosarcoma, Grade 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to assess the oncological outcomes in patients diagnosed with grade 2 chondrosarcoma, treated with intralesional curettage, stratified into two cohorts: those subjected to follow up monitoring and those who have undergone subsequent surgical intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06714773 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Last refreshed: 4 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06714773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing